What is Ispecimen?
iSpecimen operates at the intersection of healthcare data and life science research, providing a sophisticated marketplace that connects researchers with essential human biospecimens. By leveraging a vast network of healthcare organizations, the company addresses the critical bottleneck in medical R&D: the efficient, compliant, and rapid procurement of high-quality biological samples. Their platform serves as a digital infrastructure that transforms how clinical data and physical specimens are accessed, ultimately reducing the time-to-market for life-saving therapies and diagnostic tools. As a leader in this niche, iSpecimen is effectively digitizing the supply chain for precision medicine.
How much funding has Ispecimen raised?
Ispecimen has raised a total of $16.2M across 6 funding rounds:
Series A
$2M
Series B
$8.6M
Debt
$350K
Debt
$1M
Stock/Share Issuance
$1.8M
Stock/Share Issuance
$2.5M
Series A (2012): $2M with participation from MassChallenge
Series B (2014): $8.6M led by OneBlood
Debt (2020): $350K supported by PPP
Debt (2024): $1M, investors not publicly disclosed
Stock/Share Issuance (2025): $1.8M, investors not publicly disclosed
Stock/Share Issuance (2026): $2.5M, investors not publicly disclosed
Key Investors in Ispecimen
MassChallenge
MassChallenge is an organization dedicated to accelerating solutions in various sectors including Healthcare and Life Sciences, providing support to founders through programs that enhance access, insight, and relationships necessary for startup growth.
OneBlood
OneBlood, headquartered in Orlando, Florida, is a non-profit organization that specializes in blood donation for hospitals.
What's next for Ispecimen?
With the recent influx of capital, iSpecimen is poised to enhance its marketplace capabilities and deepen its integration with global healthcare networks. The strategic focus will likely center on scaling its data-driven procurement engine to meet the rising demand for specialized biospecimens in oncology, immunology, and genomic research. By optimizing its operational efficiency and expanding its reach, the company is well-positioned to maintain its competitive advantage in the life sciences ecosystem. Future growth will likely be driven by increased adoption of its platform among pharmaceutical developers and academic research centers seeking to accelerate their clinical trial timelines through reliable, high-fidelity specimen access.
See full Ispecimen company page
